Attention-Deficit Hyperactivity Disorder in Children and Youth: A Quantitative Systematic Review of the Efficacy of Different Management Strategies

Klassen, Anne F.; Miller, Anton R.; Raina, Parminder; Lee, Shoo K.; Olsen, Lise

doi:10.1177/070674379904401007

Cited by 58 publications

(27 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We test ed for a sig nif i cant differ ence in mar gin al WTP val ues in each group of stu dents, name ly, in the ab solute dif fer ence (ab s d iff) be tween WTP for stan dard drug 1 and WTP for new drug 2, and that be tween WTP for new drug 1 and WTP for stan dard drug 2 : WTP stan dard drug 1 −WTP new drug 2 =ab s d iff 1 , WTP new drug 1 −WTP stan dard drug 2 = ab s d iff 2 . The dif fer ence be tween ab s d iff 1 and ab s d iff 2 was found to be very small (€26.28 vs. €25.65, P=0.946, in de pen dentsam ples t test; . Ta ble 2); mar gin al WTP was thus ap prox i mate ly the same for the two groups of re spon dents.…”

Section: De Scrip Tive Sta Tis Tics and Test Re Sults In Group 1 (Stamentioning

confidence: 91%

See 1 more Smart Citation

Order bias in estimates of willingness to pay for drugs to treat attention-deficit/hyperactivity disorder

Ridder

Graeve

2005

Eur J Health Econ

View full text Add to dashboard Cite

This study investigated the presence of order bias in contingent valuation studies. We compared the willingness to pay (WTP) for an improved drug for attention-deficit/hyperactivity disorder with that for the standard drug and examined whether the order in which the drugs are presented influences the results obtained. A pretested questionnaire was administered to 114 university students. WTP was elicited using the payment card method. A split sample was used to test order bias. The average WTP per month was euro 57.34 for the standard drug and euro 81.95 for the new drug. The results show that WTP for a new drug varies according to the order in which the drugs are presented. Respondents stated a higher WTP for the new drug if the standard therapy was presented first. This may be due to order bias, evidence of which has also been found in other studies and which is considered to be a limitation of the method. Finally, the use of marginal WTP is suggested as a solution.

show abstract

Section: De Scrip Tive Sta Tis Tics and Test Re Sults In Group 1 (Stamentioning

confidence: 91%

“…It is es ti mat ed to oc cur in 3-5 of the school-aged pop u la tion [1,2]. The dis order has three prin ci pal fea tures: dif fi cul ty in con cen trat ing for long pe ri ods of time (inat ten tion), ex ces sive move ment (hy perac tiv i ty), and act ing with out think ing (impul sive ness) [2].…”

mentioning

confidence: 99%

Order bias in estimates of willingness to pay for drugs to treat attention-deficit/hyperactivity disorder

Ridder

Graeve

2005

Eur J Health Econ

View full text Add to dashboard Cite

show abstract

“…[52][53][54][55][56] Most of the studies comparing short and long-acting methylphenidate compounds found no significant differences in effect sizes. 55,57 However, a meta-analysis looking at medications for adults with ADHD found that the clinical response for short-acting stimulants was greater than for long-acting stimulants.…”

Section: Efficacy Of Interventionsmentioning

confidence: 99%

Developments and challenges in the diagnosis and treatment of ADHD

Dias

Kieling

Graeff-Martins

et al. 2013

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder, often associated with other psychiatric comorbidities, functional impairments, and poor long-term outcomes. The objective of this selected review is to describe current advances and challenges in the diagnosis and treatment of ADHD. The disorder is associated with neurobiological underpinnings and is highly heterogeneous in various aspects, such as symptom profiles, cognitive impairments, and neurobiological and genetic features. The efficacy and safety of short-term pharmacological treatments across the life cycle is well studied, but further research investigating long-term treatment, impact of treatment in preschoolers, and non-pharmacological interventions is needed. Future research is also needed to better characterize the neurodevelopmental pathways of the disorder, linking clinical and neurobiological information, less investigated populations, and new interventions.

show abstract

“…26 Short-term trials of stimulants support their efficacy, with response rates in the 70%-to-90% range. 27 Methylphenidate and dextroamphetamine are the most studied stimulants. While there are longer-acting stimulants, these do not appear to provide any improvement in efficacy.…”

Section: Treatmentmentioning

confidence: 99%